Computational Studies Applied to Linalool and Citronellal Derivatives Against Alzheimer's and Parkinson's Disorders: A Review with Experimental Approach

Alzheimer's and Parkinson's are neurodegenerative disorders that affect a great number of people around the world, seriously compromising the quality of life of individuals, due to motor and cognitive damage. In these diseases, pharmacological treatment is used only to alleviate symptoms. This emphasizes the need to discover alternative molecules for use in prevention. Using Molecular Docking, this review aimed to evaluate the anti-Alzheimer's and anti-Parkinson's activity of linalool and citronellal, as well as their derivatives. Before performing Molecular Docking simulations, the compounds' pharmacokinetic characteristics were evaluated. For Molecular Docking, 7 chemical compounds derived from citronellal, and 10 compounds derived from linalool, and molecular targets involved in Alzheimer's and Parkinson's pathophysiology were selected. According to the Lipinski rules, the compounds under study presented good oral absorption and bioavailability. For toxicity, some tissue irritability was observed. For Parkinson-related targets, the citronellal and linalool derived compounds revealed excellent energetic affinity for α-Synuclein, Adenosine Receptors, Monoamine Oxidase (MAO), and Dopamine D receptor proteins. For Alzheimer disease targets, only linalool and its derivatives presented promise against BACE enzyme activity. The compounds studied presented high probability of modulatory activity against the disease targets under study, and are potential candidates for future drugs.

Citing Articles

Impact of plant monoterpenes on insect pest management and insect-associated microbes.

Qasim M, Islam W, Rizwan M, Hussain D, Noman A, Khan K Heliyon. 2024; 10(20):e39120.

PMID: 39498017 PMC: 11532279. DOI: 10.1016/j.heliyon.2024.e39120.

Linalool, a Fragrance Compound in Plants, Protects Dopaminergic Neurons and Improves Motor Function and Skeletal Muscle Strength in Experimental Models of Parkinson's Disease.

Chang W, Hsu H, Lin C, An L, Lee C, Ko H Int J Mol Sci. 2024; 25(5).

PMID: 38473763 PMC: 10932089. DOI: 10.3390/ijms25052514.

References

Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield D . Elevation of brain glutathione by gamma-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J Neurosci Res. 2002; 68(6):776-84. DOI: 10.1002/jnr.10266. View

Moussa C . Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. Expert Opin Investig Drugs. 2017; 26(10):1131-1136. DOI: 10.1080/13543784.2017.1369527. View

Marumoto S, Okuno Y, Miyazawa M . Inhibition of β-Secretase Activity by Monoterpenes, Sesquiterpenes, and C Norisoprenoids. J Oleo Sci. 2017; 66(8):851-855. DOI: 10.5650/jos.ess16188. View

Szoko E, Tabi T, Riederer P, Vecsei L, Magyar K . Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. J Neural Transm (Vienna). 2018; 125(11):1735-1749. DOI: 10.1007/s00702-018-1853-9. View

Sun B, Feng D, Chu M, Fish I, Lovera S, Sands Z . Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist. Nat Commun. 2021; 12(1):3305. PMC: 8175458. DOI: 10.1038/s41467-021-23519-9. View

Connolly B, Lang A . Pharmacological treatment of Parkinson disease: a review. JAMA. 2014; 311(16):1670-83. DOI: 10.1001/jama.2014.3654. View

Berg S, Bergh M, Hellberg S, Hogdin K, Lo-Alfredsson Y, Soderman P . Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. J Med Chem. 2012; 55(21):9107-19. DOI: 10.1021/jm201724m. View

Kulisevsky J, Poyurovsky M . Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders. Eur Neurol. 2011; 67(1):4-11. DOI: 10.1159/000331768. View

Chandra S, Stokes A, Hailey R, Merrill C, Melich D, DeSmet K . Dermal toxicity studies: factors impacting study interpretation and outcome. Toxicol Pathol. 2014; 43(4):474-81. DOI: 10.1177/0192623314548765. View

10.

Zhuang Y, Xu P, Mao C, Wang L, Krumm B, Zhou X . Structural insights into the human D1 and D2 dopamine receptor signaling complexes. Cell. 2021; 184(4):931-942.e18. PMC: 8215686. DOI: 10.1016/j.cell.2021.01.027. View

11.

Unzeta M, Sanz E . Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease. Int Rev Neurobiol. 2011; 100:217-36. DOI: 10.1016/B978-0-12-386467-3.00011-X. View

12.

Zang X, Cheng Z, Sun Y, Hua N, Zhu L, He L . The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Aβ-induced cognitive impairment. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 81:250-261. DOI: 10.1016/j.pnpbp.2017.09.017. View

13.

Rorije E, Aldenberg T, Buist H, Kroese D, Schuurmann G . The OSIRIS Weight of Evidence approach: ITS for skin sensitisation. Regul Toxicol Pharmacol. 2013; 67(2):146-56. DOI: 10.1016/j.yrtph.2013.06.003. View

14.

Benet L, Hosey C, Ursu O, Oprea T . BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev. 2016; 101:89-98. PMC: 4910824. DOI: 10.1016/j.addr.2016.05.007. View

15.

Congreve M, Andrews S, Dore A, Hollenstein K, Hurrell E, Langmead C . Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem. 2012; 55(5):1898-903. PMC: 3308197. DOI: 10.1021/jm201376w. View

16.

Dantas de Lucena J, Gadelha-Filho C, da Costa R, de Araujo D, Lima F, Neves K . L-linalool exerts a neuroprotective action on hemiparkinsonian rats. Naunyn Schmiedebergs Arch Pharmacol. 2020; 393(6):1077-1088. DOI: 10.1007/s00210-019-01793-1. View

17.

Jankovic J, Goodman I, Safirstein B, Marmon T, Schenk D, Koller M . Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018; 75(10):1206-1214. PMC: 6233845. DOI: 10.1001/jamaneurol.2018.1487. View

18.

Balaraman Y, Limaye A, Levey A, Srinivasan S . Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol Life Sci. 2006; 63(11):1226-35. PMC: 11136440. DOI: 10.1007/s00018-005-5597-y. View

19.

Weston-Green K, Clunas H, Jimenez Naranjo C . A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis. Front Psychiatry. 2021; 12:583211. PMC: 8426550. DOI: 10.3389/fpsyt.2021.583211. View

20.

Dos Santos E, Maia C, Fontes Junior E, Melo A, Pinheiro B, Maia J . Linalool-rich essential oils from the Amazon display antidepressant-type effect in rodents. J Ethnopharmacol. 2017; 212:43-49. DOI: 10.1016/j.jep.2017.10.013. View